Abstract
Aim. To determine activity and toxicity of high-dose ifosfamide (HDIFO) in recurrent or advanced Ewing sarcoma family tumors (EFT). Methods. Thirty-seven EFT patients [median age 17 years (645 years)] previously treated with chemotherapy regimens including standard dose ifosfamide were enrolled. HDIFO was administered for metastatic recurrent disease in 33 patients and for progression during neoadjuvant chemotherapy in 4 patients. All patients who received two courses of 15 g/m2 ifosfamide were evaluable for radiographic response assessed according to RECIST criteria. Results. Transient Grade 4 neutropenia and thrombocytopenia in 97% and 54% HDIFO courses respectively and severe CNS toxicity in one patient were observed. Thirty-five patients were evaluable: 12 (34%) had complete (2) or partial (10) response, 11 (32%) had stable disease, and 12 (34%) had progression. Conclusions. In patients with relapsed or advanced EFT previously treated with standard dose ifosfamide HDIFO is active and it should be considered a treatment option.
| Original language | English |
|---|---|
| Pages (from-to) | 581-584 |
| Number of pages | 4 |
| Journal | Pediatric Blood and Cancer |
| Volume | 52 |
| Issue number | 5 |
| DOIs | |
| Publication status | Published - May 2009 |
Fingerprint
Keywords
- Ewing sarcoma family tumors
- High-dose ifosfamide
- Radiographic response
- Toxicity
ASJC Scopus subject areas
- Medicine(all)
- Hematology
- Oncology
- Pediatrics, Perinatology, and Child Health
Cite this
Response to high-dose ifosfamide in patients with advanced/recurrent ewing sarcoma. / Ferrari, S.; Del Prever, A. Brach; Palmerini, E.; Staals, E.; Berta, M.; Balladelli, A.; Picci, P.; Fagioli, F.; Bacci, G.; Vanel, D.
In: Pediatric Blood and Cancer, Vol. 52, No. 5, 05.2009, p. 581-584.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Response to high-dose ifosfamide in patients with advanced/recurrent ewing sarcoma
AU - Ferrari, S.
AU - Del Prever, A. Brach
AU - Palmerini, E.
AU - Staals, E.
AU - Berta, M.
AU - Balladelli, A.
AU - Picci, P.
AU - Fagioli, F.
AU - Bacci, G.
AU - Vanel, D.
PY - 2009/5
Y1 - 2009/5
N2 - Aim. To determine activity and toxicity of high-dose ifosfamide (HDIFO) in recurrent or advanced Ewing sarcoma family tumors (EFT). Methods. Thirty-seven EFT patients [median age 17 years (645 years)] previously treated with chemotherapy regimens including standard dose ifosfamide were enrolled. HDIFO was administered for metastatic recurrent disease in 33 patients and for progression during neoadjuvant chemotherapy in 4 patients. All patients who received two courses of 15 g/m2 ifosfamide were evaluable for radiographic response assessed according to RECIST criteria. Results. Transient Grade 4 neutropenia and thrombocytopenia in 97% and 54% HDIFO courses respectively and severe CNS toxicity in one patient were observed. Thirty-five patients were evaluable: 12 (34%) had complete (2) or partial (10) response, 11 (32%) had stable disease, and 12 (34%) had progression. Conclusions. In patients with relapsed or advanced EFT previously treated with standard dose ifosfamide HDIFO is active and it should be considered a treatment option.
AB - Aim. To determine activity and toxicity of high-dose ifosfamide (HDIFO) in recurrent or advanced Ewing sarcoma family tumors (EFT). Methods. Thirty-seven EFT patients [median age 17 years (645 years)] previously treated with chemotherapy regimens including standard dose ifosfamide were enrolled. HDIFO was administered for metastatic recurrent disease in 33 patients and for progression during neoadjuvant chemotherapy in 4 patients. All patients who received two courses of 15 g/m2 ifosfamide were evaluable for radiographic response assessed according to RECIST criteria. Results. Transient Grade 4 neutropenia and thrombocytopenia in 97% and 54% HDIFO courses respectively and severe CNS toxicity in one patient were observed. Thirty-five patients were evaluable: 12 (34%) had complete (2) or partial (10) response, 11 (32%) had stable disease, and 12 (34%) had progression. Conclusions. In patients with relapsed or advanced EFT previously treated with standard dose ifosfamide HDIFO is active and it should be considered a treatment option.
KW - Ewing sarcoma family tumors
KW - High-dose ifosfamide
KW - Radiographic response
KW - Toxicity
UR - http://www.scopus.com/inward/record.url?scp=63649140230&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=63649140230&partnerID=8YFLogxK
U2 - 10.1002/pbc.21917
DO - 10.1002/pbc.21917
M3 - Article
C2 - 19142994
AN - SCOPUS:63649140230
VL - 52
SP - 581
EP - 584
JO - Pediatric Blood and Cancer
JF - Pediatric Blood and Cancer
SN - 1545-5009
IS - 5
ER -